Case Studies

Challenge: A private biotech company with first in class, early lead compounds targeting a novel metabolic signaling protein engaged Alacrita’s NASH consultant to explore the best disease pathways...

Project: For a listed US biotech company with marketed products, Alacrita's pediatric oncologist consultant provided ongoing support with Phase I/II design, protocol development and medical oversight...

Challenge: Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to...

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.

Challenge A well-capitalized cancer immunotherapy company, operating in a highly competitive field, needed to benchmark its financial status and staff numbers against its peers to help gauge its...

Challenge A European Biotech company with its lead product being developed for a rare oncology disease in Phase 1 wanted to understand how to optimize and evaluate the commercial potential of the...

Challenge A research-based biotech needed a clear understanding of the processes, resources and timelines to establish a global pharma supply chain for their leading pipeline compound, a therapy for...

Challenge A late stage biotech needed a clear understanding of the processes, resource needs and timelines to establish global commercial operations to launch their leading pipeline compound, a...

Challenge A small, Swiss-based biotechnology company with a pre-commercial pipeline of therapeutic antibodies for rare and ultra-rare diseases was preparing to launch its first asset. This company...

Challenge A new academic spin-out company in Europe had acquired the rights to the intellectual property covering a new diagnostic agent. This molecular MRI imaging tool is envisioned to be useful in...

Challenge Dual-energy X-ray absorptiometry (DXA) has been used extensively in clinical trials in osteoporosis. DXA is increasingly being used to examine bone density in trials of drugs that could...

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...